Quanterix Cooperates with Kent Lake Capital, Seeks New Board Member.

Quanterix has entered a cooperation agreement with Kent Lake Capital to identify a new independent board member by December 1, 2025. The company will seek shareholder approval to de-classify its board of directors and adopt a majority voting standard in uncontested director elections. The agreement aims to improve corporate governance and address concerns raised by Kent Lake.

Billerica, Mass. -- Quanterix Corporation (NASDAQ: QTRX), a global leader in ultra-sensitive biomarker detection, has entered into a cooperation agreement with Kent Lake Partners LP (together with its affiliates, "Kent Lake"). Under the agreement, Quanterix will appoint a new independent director by December 1, 2025, and will seek shareholder approval to declassify its board and adopt a majority voting standard for uncontested director elections. Kent Lake has agreed to withdraw its director nominations and shareholder proposals previously submitted in connection with the Annual Meeting and will support the board's candidates [1].

The agreement aims to improve corporate governance and address concerns raised by Kent Lake. William P. Donnelly, Chairman of the Quanterix Board, stated, "We are pleased to have reached a constructive agreement with Kent Lake that will allow the Board and management team to remain fully focused on executing the Company’s strategy, navigating the dynamic industry environment and maximizing the benefits of the Akoya transaction" [1].

Benjamin Natter, Managing Member of Kent Lake, said, "We are confident that the addition of a new independent director and governance enhancements will benefit the Company and its stockholders and help position Quanterix for continued success" [1].

Quanterix's proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. The company's acquisition of Akoya Biosciences in 2025 added multiplexed tissue imaging with single-cell resolution to its portfolio, offering a uniquely integrated platform that connects biology across blood and tissue [1].

The full cooperation agreement between Quanterix and Kent Lake will be filed with the U.S. Securities and Exchange Commission on a Current Report on Form 8-K.

References:
[1] https://www.businesswire.com/news/home/20250804885724/en/Quanterix-Announces-Cooperation-Agreement-with-Kent-Lake-Capital